Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Diaceutics's pretax income for the
six
months ended in Dec. 2025 was $4.44 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was $0.35 Mil.
Diaceutics's pretax margin was 13.89%.
During the past 10 years, Diaceutics's highest Pretax Margin was 17.11%. The lowest was -10.29%. And the median was 3.10%.
During the past 10 years, Diaceutics's highest Pretax Margin was 17.11%. The lowest was -10.29%. And the median was 3.10%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics Pre-Tax Income Related Terms
Diaceutics Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Diaceutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DIUXF vs VEEV, BTSG, HQY: Pre-Tax Income Comparison
For the Health Information Services subindustry, Diaceutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Pre-Tax Income vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Diaceutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (DIUXF) has a Pre-Tax Income of $0.35 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Diaceutics and its competitors.
Is Diaceutics' Pre-Tax Income too high?
Diaceutics' current Pre-Tax Income is $0.35 Mil. Overall, Diaceutics has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Pre-Tax Income compare to VEEV and BTSG?
Diaceutics' Pre-Tax Income of $0.35 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Healthcare Providers & Services company?
A good Pre-Tax Income depends on the Healthcare Providers & Services industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Diaceutics and its competitors. Diaceutics's current Pre-Tax Income is $0.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Diaceutics (DIUXF) has a current Pre-Tax Income of $0.35 Mil. The stock's GF Value™ is $2.55, compared to a current price of $2.00 — trading 21.6% below its estimated fair value. The current Pre-Tax Income is $0.35 Mil. Diaceutics' overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Pre-Tax Income is $0.35 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 21.6% below its estimated GF Value™ of $2.55.
Key valuation signals for DIUXF:
Pre-Tax Income: $0.35 Mil
GF Value™: $2.55 vs. price of $2.00 (21.6% below fair value)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
87GF Score
Get the complete analysis for DIUXF
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
